AML consolidation therapy: timing matters

PURPOSE: Infections due to severe neutropenia are the most common therapy-associated causes of mortality in patients with acute myeloid leukemia (AML). New strategies to lessen the severity and duration of neutropenia are needed. METHODS: Cytarabine is commonly used for AML consolidation therapy; we...

Descripción completa

Detalles Bibliográficos
Autores principales: Reimann, Adrian-Manuel, Schalk, Enrico, Jost, Felix, Mougiakakos, Dimitrios, Weber, Daniela, Döhner, Hartmut, Récher, Christian, Dumas, Pierre-Yves, Ditzhaus, Marc, Fischer, Thomas, Sager, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590325/
https://www.ncbi.nlm.nih.gov/pubmed/37535164
http://dx.doi.org/10.1007/s00432-023-05115-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590325/
https://www.ncbi.nlm.nih.gov/pubmed/37535164
http://dx.doi.org/10.1007/s00432-023-05115-0

Ejemplares similares